Tjalke A Westra

Summary

Affiliation: University Medical Center Groningen
Country: The Netherlands

Publications

  1. doi request reprint Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands
    Tjalke A Westra
    Department of Pharmacy, University of Groningen, The Netherlands
    Clin Ther 32:1479-95. 2010
  2. doi request reprint Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses
    Tjalke A Westra
    Department of Medical Microbiology Molecular Virology, University Medical Center Groningen, The Netherlands
    J Infect Dis 204:377-84. 2011
  3. doi request reprint Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 11:1415-28. 2012
  4. doi request reprint On discounting of health gains from human papillomavirus vaccination: effects of different approaches
    Tjalke A Westra
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Value Health 15:562-7. 2012
  5. pmc Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands
    Tjalke A Westra
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Antonius Deusinglaan 1, 9713AV, Groningen, The Netherlands
    BMC Infect Dis 13:75. 2013
  6. pmc Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model
    Robin de Vries
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    PLoS ONE 5:e13392. 2010
  7. doi request reprint Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples
    Maarten J Postma
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 12:555-65. 2013
  8. pmc Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands
    Hiltsje Hepkema
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    PLoS ONE 8:e65036. 2013

Detail Information

Publications8

  1. doi request reprint Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands
    Tjalke A Westra
    Department of Pharmacy, University of Groningen, The Netherlands
    Clin Ther 32:1479-95. 2010
    ..Because pertussis is most severe in unimmunized infants and infants who have only received some of the recommended doses, new pertussis immunization strategies should be considered to protect this vulnerable population...
  2. doi request reprint Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses
    Tjalke A Westra
    Department of Medical Microbiology Molecular Virology, University Medical Center Groningen, The Netherlands
    J Infect Dis 204:377-84. 2011
    ..Accordingly, it has been suggested that these older women should also be offered vaccination. Here, the cost-effectiveness of HPV vaccination for older women was assessed...
  3. doi request reprint Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 11:1415-28. 2012
    ..In future, dynamic transmission models for pertussis should be used widely to further enhance understanding of pertussis epidemiology and of extended pertussis vaccination programs that are currently considered in various countries...
  4. doi request reprint On discounting of health gains from human papillomavirus vaccination: effects of different approaches
    Tjalke A Westra
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Value Health 15:562-7. 2012
    ..Different approaches to discount health effects have been proposed. In this study, we estimated the impact of different approaches for discounting health benefits of human papillomavirus (HPV) vaccination...
  5. pmc Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands
    Tjalke A Westra
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Antonius Deusinglaan 1, 9713AV, Groningen, The Netherlands
    BMC Infect Dis 13:75. 2013
    ..In this study, we made an analytical comparison of the two vaccines in terms of cost-effectiveness including the additional benefits of cross-protection and protection against genital warts in comparison with a screening-only strategy...
  6. pmc Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model
    Robin de Vries
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    PLoS ONE 5:e13392. 2010
    ..Using this framework, we estimate the cost-effectiveness of universal adolescent pertussis booster vaccination at the age of 12 years in the Netherlands...
  7. doi request reprint Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples
    Maarten J Postma
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 12:555-65. 2013
    ..Finally, the need for sometimes complex dynamic models for vaccines is explored, and specific types of models are reviewed, keeping into consideration the adage "complex when needed, straightforward if allowed."..
  8. pmc Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands
    Hiltsje Hepkema
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    PLoS ONE 8:e65036. 2013
    ..Despite its success, herd immunity may wane over time. Recently, a serogroup A,C,W135,Y meningococcal conjugate vaccine (MenACWY) was licensed for use in subjects of 12 months of age and above...